Nutritional, phytochemical and pharmacological attributes of seven Ficus species: current evidence and future prospects

Ficus fruits represent a promising yet underexplored group of edible medicinal resources within the Moraceae family. Key findings include, Ficus assamica and F. hispida exhibit exceptionally high phenolic and flavonoid concentrations; F. semicordata demonstrates a superior mineral profile; F. racemosa and F. auriculata show promising antidiabetic potential and F. fistulosa extract has already been tested clinically in a topical hydrogel that significantly reduced facial sebum without irritation. The most advanced pharmacological lead comes from F. simplicissima, whose coumarin compound bergapten, formulated as liposomes (Ber-lipo), has shown protective effects against lipopolysaccharide (LPS)-induced acute lung injury through modulation of macrophage activity and inflammatory signaling pathways. Despite these promising findings, research on Ficus fruits remains fragmented. Many studies lack standardised extraction methods, detailed sampling metadata or quantitative analysis of individual bioactive compounds. Toxicological data, pharmacokinetic profiles and controlled clinical trials are almost absent. To bridge these gaps, future research should prioritise standardised methodologies, comprehensive metabolomic profiling, safety and contaminant analyses and well-designed human studies to validate efficacy. With these advancements, Ficus fruits hold significant potential as nutraceutical and therapeutic resources for metabolic, inflammatory and respiratory health.